GAMMA: A genetic-clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation
A genetic model helps doctors identify which leukemia patients face the highest risk after stem cell transplant, potentially guiding treatment intensity.
This PubMed-indexed observational/cohort study examined GAMMA: A genetic-clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation. The abstract reports that a total of 297 R/R AML patients from 11 other HSCT centers in China were included in the external validation group.
What the study was
- Study design
- Observational/cohort study
- Population
- GAMMA: A genetic-clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cancer letters
Why it surfaced
Observational/cohort study with an abstract-supported finding relevant to Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); scored conservatively because only the PubMed abstract was reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.